Dorian LPG
LPG
YETI Holdings
YETI
Workday
WDAY
4
Collegium Pharmaceutical
COLL
5
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
US Stock MarketDetailed Quotes
DTIL Precision BioSciences
- 4.9800
- -0.0700-1.39%
Close Mar 18 16:00 ET
38.20MMarket Cap-17.79P/E (TTM)
5.0050High4.8100Low59.70KVolume4.9700Open5.0500Pre Close294.82KTurnover1.00%Turnover RatioLossP/E (Static)7.67MShares15.970052wk High0.59P/B29.68MFloat Cap3.610052wk Low--Dividend TTM5.96MShs Float710.1060Historical High--Div YieldTTM3.86%Amplitude3.6100Historical Low4.9380Avg Price1Lot Size
Trending Stocks
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve
Moo Earnings
Feb 2 12:39
AMZN earnings preview: Grab rewards by guessing the opening price!
Precision BioSciences Stock Forum
Preclinical data to be presented at the 2025 Muscular Dystrophy Association (MDA) - possible catalyst date 03/19/2025
*nfa
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class Pbgene-Hbv Designed to Eliminate Root Cause of Chronic Hepatitis B
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B
Monday, 17th March at 7:01 am
- PBGENE-HBV is the first-ever investigational in vivo gene editing therapy cleared to enter clinical trials for the treatment of chronic hepatitis B in the United States (U.S.) –
- IND clearance represents a significant regulatory milestone for P...
Breakthrough: First Baby Shows Complete Response to Gene Editing Treatment for Fatal Genetic Disease
The initial results from Precision BioSciences' ELIMINATE-B trial represent a significant breakthrough in gene editing therapeutics for chronic Hepatitis B. The demonstration of both safety and efficacy signals at the lowest dose level (0.2 mg/kg) is particularly noteworthy for several reasons:
The safety profile is remarkably clean, with no Grade ≥2 treatment-related adverse events or serious adverse events reported. This is important ...
Revolutionary Gene Therapy Achieves First-Ever ARCUS Success Against Hepatitis B - What's Next?
Precision BioSciences Announces Initial Safety and Antiviral Activity of Pbgene-Hbv in the Eliminate-B Clinical Trial
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER...
No comment yet